Table 1.

Patient characteristics (n = 19)

Age, y, median (range)61 (50–78)
Sex, n
 Women12
 Men7
Months from beginning erlotinib/gefitinib, median (range)22 (5–72)
EGFR mutation, n
 Exon 19 deletion12
 Exon 21 L858R mutation4
 Negative1
 Unknown2
EGFR T790M acquired mutation, n
 Yes9
 No3
 Unknown7